Fennec Pharmaceuticals rises on EU regulator backing for hearing loss therapy

Fennec Pharmaceuticals

31/03/2023 14:49

** Shares of Fennec Pharmaceuticals Inc  FENC.O  rise 3.2%
to $8.82 
    ** Co says the Committee for Medicinal Products for Human
Use (CHMP) of the European Medicines Agency (EMA) has issued a
positive opinion and recommended granting a marketing
authorization for its hearing loss therapy pedmarqsi
    ** The therapy, which is approved as Pedmark in the U.S, is
for the prevention of hearing loss induced by chemotherapy in
children aged over one month who have undergone chemotherapy
using the drug cisplatin
    ** When formally approved by the European Commission,
pedmarqsi will be the first and only treatment approved in the
EU - co
    ** The review of CHMP's recommendation is expected by early
June 2023
    ** Despite sessions gains, stock down ~11% YTD

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))